

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830  
Date of issue: 9/5/2018 Revision date: 3/20/2019 Supersedes: 9/5/2018 Version: 1.1

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

Product form : Substance  
Substance name : Rifampicin  
Chemical name : Rifampicin  
EC-No. : 236-312-0  
CAS-No. : 13292-46-1  
Product code : 32609202  
Formula : C43H58N4O12

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

##### 1.2.1. Relevant identified uses

Industrial/Professional use spec : Industrial  
For professional use only

##### 1.2.2. Uses advised against

No additional information available

#### 1.3. Details of the supplier of the safety data sheet

Scafell Organics  
Molekula Ltd  
Lingfield Way  
Darlington - England  
T +44 (0) 1949 823777 / +44 (0) 7590 545705  
[info@molekula.com](mailto:info@molekula.com) / [kbowen@molekula.com](mailto:kbowen@molekula.com) - [www.molekula.com](http://www.molekula.com)

#### 1.4. Emergency telephone number

Emergency number : +44 (0) 7590 545705

### SECTION 2: Hazards identification

#### 2.1. Classification of the substance or mixture

##### Classification according to Regulation (EC) No. 1272/2008 [CLP]

Acute toxicity (oral), Category 4 H302  
Skin corrosion/irritation, Category 2 H315  
Serious eye damage/eye irritation, Category 2 H319  
Specific target organ toxicity — Single exposure, Category 3, Respiratory tract irritation H335  
Full text of H statements : see section 16

##### Adverse physicochemical, human health and environmental effects

No additional information available

#### 2.2. Label elements

##### Labelling according to Regulation (EC) No. 1272/2008 [CLP]

Hazard pictograms (CLP) :



GHS07

Signal word (CLP)

: Warning

Hazard statements (CLP)

: H302 - Harmful if swallowed.  
H315 - Causes skin irritation.  
H319 - Causes serious eye irritation.  
H335 - May cause respiratory irritation.

Precautionary statements (CLP)

: P261 - Avoid breathing dust/fume/gas/mist/vapours/spray.  
P280 - Wear protective clothing, eye protection, face protection.  
P301+P330+P331 - IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.  
P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308+P313 - IF exposed or concerned: Get medical advice/attention.

#### 2.3. Other hazards

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII

This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

### SECTION 3: Composition/information on ingredients

#### 3.1. Substances

Name	Product identifier	%
Rifampicin	(CAS-No.) 13292-46-1 (EC-No.) 236-312-0	100

Full text of H-statements: see section 16

#### 3.2. Mixtures

Not applicable

### SECTION 4: First aid measures

#### 4.1. Description of first aid measures

First-aid measures general	: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).
First-aid measures after inhalation	: Remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Get medical advice/attention.
First-aid measures after skin contact	: Rinse skin with water/shower. If skin irritation or rash occurs: Get medical advice/attention.
First-aid measures after eye contact	: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.
First-aid measures after ingestion	: Rinse mouth. Do NOT induce vomiting. Get medical advice/attention.

#### 4.2. Most important symptoms and effects, both acute and delayed

Symptoms/effects after inhalation	: Inhalation may cause irritation (cough, short breathing, difficulty in breathing).
Symptoms/effects after skin contact	: irritation (itching, redness, blistering).
Symptoms/effects after eye contact	: Causes serious eye irritation. redness, itching, tears.
Symptoms/effects after ingestion	: Harmful if swallowed. Ingestion may cause nausea, vomiting and diarrhea.

#### 4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

### SECTION 5: Firefighting measures

#### 5.1. Extinguishing media

Suitable extinguishing media	: Foam. Dry powder. Carbon dioxide. Water spray. Sand.
Unsuitable extinguishing media	: Do not use a heavy water stream.

#### 5.2. Special hazards arising from the substance or mixture

Hazardous decomposition products in case of fire	: Carbon oxides (CO, CO <sub>2</sub> ). Nitrogen oxides.
--	--

#### 5.3. Advice for firefighters

Precautionary measures fire	: Evacuate area. Keep container tightly closed and away from heat, sparks and flame. Eliminate all ignition sources if safe to do so.
Firefighting instructions	: Use water spray or fog for cooling exposed containers. Exercise caution when fighting any chemical fire. Prevent fire fighting water from entering the environment.
Protection during firefighting	: Do not enter fire area without proper protective equipment, including respiratory protection.
Other information	: Warn all persons of toxic hazard.

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

General measures	: Isolate from fire, if possible, without unnecessary risk. No flames, no sparks. Eliminate all sources of ignition. Avoid dust formation.
------------------	--

##### 6.1.1. For non-emergency personnel

Protective equipment	: Wear recommended personal protective equipment.
Emergency procedures	: Evacuate unnecessary personnel. Mark out the contaminated area with signs and prevent access to unauthorized personnel. Avoid contact with skin, eyes and clothing. Do not breathe dust. Do not touch or walk on the spilled product.
Measures in case of dust release	: Keep upwind. Ventilate the area thoroughly, especially low lying areas (basements, workpits etc).

##### 6.1.2. For emergency responders

Protective equipment	: Equip cleanup crew with proper protection. Use self-contained breathing apparatus and chemically protective clothing.
Emergency procedures	: Ventilate area. Stop leak if safe to do so.

#### 6.2. Environmental precautions

Prevent entry to sewers and public waters. Notify authorities if liquid enters sewers or public waters.

#### 6.3. Methods and material for containment and cleaning up

Methods for cleaning up	: On land, sweep or shovel into suitable containers. Minimise generation of dust. Store away from other materials.
-------------------------	--

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

### 6.4. Reference to other sections

See Heading 8. Exposure controls and personal protection.

## SECTION 7: Handling and storage

### 7.1. Precautions for safe handling

Precautions for safe handling	: Handle under inert gas. Protect from moisture. Provide local exhaust or general room ventilation. Avoid breathing dust. Do not get in eyes, on skin, or on clothing.
Hygiene measures	: Always wash hands after handling the product. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Take off immediately all contaminated clothing and wash it before reuse. Wash contaminated clothing before reuse.

### 7.2. Conditions for safe storage, including any incompatibilities

Technical measures	: Provide local exhaust or general room ventilation.
Storage conditions	: Keep only in the original container in a cool, well ventilated place away from : Direct sunlight, Heat sources. Keep contents under inert gas.
Incompatible products	: Strong oxidisers.
Incompatible materials	: Direct sunlight. Heat sources. Moisture.
Storage temperature	: -20 °C
Storage area	: Store in dry protected location to prevent any moisture contact.

### 7.3. Specific end use(s)

No additional information available

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

No additional information available

### 8.2. Exposure controls

#### Appropriate engineering controls:

Handle in accordance with good industrial hygiene and safety procedures. Provide local exhaust or general room ventilation.

#### Personal protective equipment:

Wear recommended personal protective equipment.

#### Materials for protective clothing:

Use chemically protective clothing

#### Hand protection:

The protective gloves to be used must comply with the specifications of the regulation 2016/425 and the resultant standard EN 374. Always wash hands after handling the product

Type	Material	Permeation	Thickness (mm)	Penetration	Standard
	Nitrile rubber (NBR)	6 (> 480 minutes)	0.11 mm minimum		EN 374

#### Eye protection:

Emergency eye wash fountains should be available in the immediate vicinity of any potential exposure

Type	Use	Characteristics	Standard
Safety glasses	Dust	With side shields	EN 166

#### Skin and body protection:

Emergency safety showers should be available in the immediate vicinity of any potential exposure

Type	Standard
Total impervious protective suits, gloves, and boots must be worn to prevent any contact with the product	EN ISO 13982

#### Respiratory protection:

Keep self contained breathing apparatus readily available for emergency use.

Device	Filter type	Condition	Standard
Respiratory protective device with a particle filter	Type P1, Type P2	Dust protection	EN 143

#### Other information:

Do not eat, drink or smoke during use.

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

### SECTION 9: Physical and chemical properties

#### 9.1. Information on basic physical and chemical properties

Physical state	: Solid
Appearance	: Powder.
Molecular mass	: 822.94 g/mol
Colour	: orange. red. brown.
Odour	: Odourless; cannot be detected by sense of smell.
Odour threshold	: No data available
pH	: No data available
Relative evaporation rate (butylacetate=1)	: No data available
Melting point	: 183 - 194 °C
Freezing point	: No data available
Boiling point	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Flammability (solid, gas)	: Non flammable.
Vapour pressure	: No data available
Relative vapour density at 20 °C	: No data available
Relative density	: No data available
Solubility	: Slightly soluble in: Water. Soluble in : Dimethylsulfoxide (DMSO). ethyl acetate. methanol. Tetrahydrofuran.
Log Pow	: No data available
Viscosity, kinematic	: No data available
Viscosity, dynamic	: No data available
Explosive properties	: No data available.
Oxidising properties	: No data available.
Explosive limits	: No data available

#### 9.2. Other information

No additional information available

### SECTION 10: Stability and reactivity

#### 10.1. Reactivity

The product is non-reactive under normal conditions of use, storage and transport.

#### 10.2. Chemical stability

Stable under recommended handling and storage conditions (see section 7).

#### 10.3. Possibility of hazardous reactions

No dangerous reactions known under normal conditions of use.

#### 10.4. Conditions to avoid

Direct sunlight. Heat sources. Moisture.

#### 10.5. Incompatible materials

Strong oxidizers.

#### 10.6. Hazardous decomposition products

Under normal conditions of storage and use, hazardous decomposition products should not be produced. Thermal decomposition generates : Carbon oxides (CO, CO<sub>2</sub>). Nitrogen oxides.

### SECTION 11: Toxicological information

#### 11.1. Information on toxicological effects

Acute toxicity (oral)	: Oral: Harmful if swallowed.
Acute toxicity (dermal)	: Not classified
Acute toxicity (inhalation)	: Not classified

#### Rifampicin (13292-46-1)

LD50 oral rat	1570 mg/kg
Skin corrosion/irritation	: Causes skin irritation.
Serious eye damage/irritation	: Causes serious eye irritation.
Respiratory or skin sensitisation	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Germ cell mutagenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

Carcinogenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Reproductive toxicity	: Not classified
STOT-single exposure	: May cause respiratory irritation.
STOT-repeated exposure	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Aspiration hazard	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Potential adverse human health effects and symptoms	: Harmful if swallowed. Harmful in contact with skin.

### SECTION 12: Ecological information

#### 12.1. Toxicity

Acute aquatic toxicity	: Not classified
Chronic aquatic toxicity	: Not classified

#### 12.2. Persistence and degradability

##### Rifampicin (13292-46-1)

Persistence and degradability	No data available.
-------------------------------	--------------------

#### 12.3. Bioaccumulative potential

##### Rifampicin (13292-46-1)

Bioaccumulative potential	No data available.
---------------------------	--------------------

#### 12.4. Mobility in soil

No additional information available

#### 12.5. Results of PBT and vPvB assessment

##### Rifampicin (13292-46-1)

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII

This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII

#### 12.6. Other adverse effects

Additional information	: Avoid release to the environment.
------------------------	-------------------------------------

### SECTION 13: Disposal considerations

#### 13.1. Waste treatment methods

Product/Packaging disposal recommendations	: Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.
--	---

### SECTION 14: Transport information

In accordance with ADR / RID / IMDG / IATA / ADN

ADR	IMDG	IATA	ADN	RID
<b>14.1. UN number</b>				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
<b>14.2. UN proper shipping name</b>				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
<b>14.3. Transport hazard class(es)</b>				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
<b>14.4. Packing group</b>				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
<b>14.5. Environmental hazards</b>				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated

No supplementary information available

#### 14.6. Special precautions for user

##### Overland transport

Not regulated

# Rifampicin

## Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

### Transport by sea

Not regulated

### Air transport

Not regulated

### Inland waterway transport

Not regulated

### Rail transport

Not regulated

### 14.7. Transport in bulk according to Annex II of Marpol and the IBC Code

Not applicable

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### 15.1.1. EU-Regulations

No REACH Annex XVII restrictions

Rifampicin is not on the REACH Candidate List

Rifampicin is not on the REACH Annex XIV List

Directive 2012/18/EU (SEVESO III)

#### 15.1.2. National regulations

No additional information available

### 15.2. Chemical safety assessment

No chemical safety assessment has been carried out

## SECTION 16: Other information

Data sources : REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.

Other information : None.

Full text of H- and EUH-statements:	
Acute Tox. 4 (Oral)	Acute toxicity (oral), Category 4
Eye Irrit. 2	Serious eye damage/eye irritation, Category 2
Skin Irrit. 2	Skin corrosion/irritation, Category 2
STOT SE 3	Specific target organ toxicity — Single exposure, Category 3, Respiratory tract irritation
H302	Harmful if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.

SDS EU (REACH Annex II)

*This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.*